ATXS – astria therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE [Yahoo! Finance]
Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis [Yahoo! Finance]
Form 8-K Astria Therapeutics, For: Dec 17
Form SC 13G/A Astria Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A Astria Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Form SC 13D/A Astria Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC
Form SC 13G/A Astria Therapeutics, Filed by: Fairmount Funds Management LLC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.